Who owns BioCryst Pharmaceuticals?

Who owns BioCryst Pharmaceuticals?

State Street Global Advisors, Inc. is currently the largest shareholder, with 10% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 9.0% of common stock, and Baker Bros. Advisors LP holds about 7.2% of the company stock.

Similarly, Where is BioCryst located?

BioCryst’s US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.

What is BioCryst Pharmaceuticals working on? BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg …

Thereof, How many shares does BioCryst have?

BioCryst Pharmaceuticals, Inc. (US:BCRX) has 434 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 134,847,616 shares.

How many employees does BioCryst have?

BioCryst Pharmaceuticals

Type Public
Key people Jon P. Stonehouse , President and Chief Executive Officer
Products RABIVAP
Revenue $49 Million(2019)
Number of employees 110

Join TheMoney.co community and don’t forget to share this post !

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.